Blocking the pyrimidine metabolism pathway using antimetabolic chemotherapy drugs (such as capecitabine) may have therapeutic benefits for patients with KIFC2-amplified HR+/HER2– BC. This evidence concerns the gene KIFC2 and breast cancer.